This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (9)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Oncology, Other  • Hepatobiliary Surgery  • Liver/ Biliary Tract/ Pancreatic Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Timothy M. Pawlik, MD, MPH; Jean-Nicolas Vauthey, MD; Eddie K. Abdalla, MD; Raphael E. Pollock, MD, PhD; Lee M. Ellis, MD; Steven A. Curley, MD

Arch Surg. 2006;141:537-544.

Hypothesis  A subset of patients with sarcoma liver metastasis may benefit from hepatic resection and/or ablation.

Design  Retrospective review of prospectively collected cancer center database records.

Patients and Methods  Sixty-six patients who underwent hepatic resection and/or open radiofrequency ablation of metastatic sarcoma between July 1, 1996, and April 30, 2005, were identified from the database. Clinicopathologic, operative, recurrence, and long-term survival data were analyzed.

Results  The primary sarcoma site was the abdomen or retroperitoneum (n = 22), stomach (n = 18), small or large bowel (n = 17), pelvis (n = 4), uterus (n = 3), or other (n = 2). Tumor pathologic types included gastrointestinal stromal tumor (n = 36), leiomyosarcoma (n = 18), and sarcoma not otherwise classified (n = 12). Thirty-five patients underwent resection, 18 underwent resection plus radiofrequency ablation, and 13 underwent radiofrequency ablation only. With a median follow-up of 35.8 months, 44 patients (66.7%) had recurrence (intrahepatic only, n = 16; extrahepatic only, n = 11; both, n = 17). Treatment with radiofrequency ablation (either alone or combined with resection) (P = .002) and lack of adjuvant chemotherapy (P = .01) predicted shorter disease-free survival. The 1-, 3-, and 5-year overall survival rates were 91.2%, 65.4%, and 27.1%, respectively. Patients with gastrointestinal stromal tumor who were treated with adjuvant imatinib mesylate had the longest median survival (not reached) (P = .003).

Conclusions  Long-term survival can be achieved following surgical treatment of sarcoma liver metastasis, especially in patients with gastrointestinal stromal tumor. Patients with sarcoma liver metastasis should be evaluated by a multidisciplinary team, as recurrence is common and adjuvant therapy may prolong survival.

Author Affiliations: Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Long-term Survival After Surgery for Primary Hepatic Sarcoma in Adults
Matthaei et al.
Arch Surg 2009;144:339-344.
ABSTRACT | FULL TEXT  

Dose Escalation of Imatinib After Failure of Standard Dose in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor
Park et al.
Jpn J Clin Oncol 2009;39:105-110.
ABSTRACT | FULL TEXT  

Pancreatic Resection of Isolated Metastases from Nonpancreatic Primary Cancers
Reddy et al.
Ann. Surg. Oncol. 2008;15:3199-3206.
ABSTRACT | FULL TEXT  

Long-Term Results of Liver Resection for Noncolorectal, Nonneuroendocrine Metastases
O'Rourke et al.
Ann. Surg. Oncol. 2008;15:207-218.
ABSTRACT | FULL TEXT  

Liver-Directed Surgery for Metastatic Squamous Cell Carcinoma to the Liver: Results of a Multi-Center Analysis
Pawlik et al.
Ann. Surg. Oncol. 2007;14:2807-2816.
ABSTRACT | FULL TEXT